224 related articles for article (PubMed ID: 9521701)
1. Mammalian DNA topoisomerase I activity and poisoning by camptothecin are inhibited by simian virus 40 large T antigen.
Pommier Y; Kohlhagen G; Wu C; Simmons DT
Biochemistry; 1998 Mar; 37(11):3818-23. PubMed ID: 9521701
[TBL] [Abstract][Full Text] [Related]
2. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.
Antony S; Jayaraman M; Laco G; Kohlhagen G; Kohn KW; Cushman M; Pommier Y
Cancer Res; 2003 Nov; 63(21):7428-35. PubMed ID: 14612542
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
Urasaki Y; Laco GS; Pourquier P; Takebayashi Y; Kohlhagen G; Gioffre C; Zhang H; Chatterjee D; Pantazis P; Pommier Y
Cancer Res; 2001 Mar; 61(5):1964-9. PubMed ID: 11280753
[TBL] [Abstract][Full Text] [Related]
4. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
Fan Y; Weinstein JN; Kohn KW; Shi LM; Pommier Y
J Med Chem; 1998 Jun; 41(13):2216-26. PubMed ID: 9632354
[TBL] [Abstract][Full Text] [Related]
5. Enhanced CPT sensitivity of yeast cells and selective relaxation of Ga14 motif-containing DNA by novel Gal4-topoisomerase I fusion proteins.
Alessandri M; Beretta GL; Ferretti E; Mancia A; Khobta A; Capranico G
J Mol Biol; 2004 Mar; 337(2):295-305. PubMed ID: 15003448
[TBL] [Abstract][Full Text] [Related]
6. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin.
Hsiang YH; Liu LF
Cancer Res; 1988 Apr; 48(7):1722-6. PubMed ID: 2832051
[TBL] [Abstract][Full Text] [Related]
7. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of resistance to topoisomerase I-targeting drugs.
Rasheed ZA; Rubin EH
Oncogene; 2003 Oct; 22(47):7296-304. PubMed ID: 14576839
[TBL] [Abstract][Full Text] [Related]
9. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site.
Urasaki Y; Laco G; Takebayashi Y; Bailly C; Kohlhagen G; Pommier Y
Cancer Res; 2001 Jan; 61(2):504-8. PubMed ID: 11212241
[TBL] [Abstract][Full Text] [Related]
10. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system.
Tsao YP; Russo A; Nyamuswa G; Silber R; Liu LF
Cancer Res; 1993 Dec; 53(24):5908-14. PubMed ID: 8261402
[TBL] [Abstract][Full Text] [Related]
11. Simian virus 40 large T antigen binds to topoisomerase I.
Simmons DT; Melendy T; Usher D; Stillman B
Virology; 1996 Aug; 222(2):365-74. PubMed ID: 8806520
[TBL] [Abstract][Full Text] [Related]
12. Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity.
Beidler DR; Cheng YC
Mol Pharmacol; 1995 May; 47(5):907-14. PubMed ID: 7538195
[TBL] [Abstract][Full Text] [Related]
13. Camptothecins inhibit the utilization of hydrogen peroxide in the ligation step of topoisomerase I catalysis.
Lisby M; Krogh BO; Boege F; Westergaard O; Knudsen BR
Biochemistry; 1998 Jul; 37(30):10815-27. PubMed ID: 9692972
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of camptothecin-induced topoisomerase I cleavage complexes by the acetaldehyde adduct N2-ethyl-2'-deoxyguanosine.
Antony S; Theruvathu JA; Brooks PJ; Lesher DT; Redinbo M; Pommier Y
Nucleic Acids Res; 2004; 32(18):5685-92. PubMed ID: 15498925
[TBL] [Abstract][Full Text] [Related]
15. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine.
Benedetti P; Fiorani P; Capuani L; Wang JC
Cancer Res; 1993 Sep; 53(18):4343-8. PubMed ID: 8395982
[TBL] [Abstract][Full Text] [Related]
16. Simian virus 40 large T-antigen G-quadruplex DNA helicase inhibition by G-quadruplex DNA-interactive agents.
Tuesuwan B; Kern JT; Thomas PW; Rodriguez M; Li J; David WM; Kerwin SM
Biochemistry; 2008 Feb; 47(7):1896-909. PubMed ID: 18205402
[TBL] [Abstract][Full Text] [Related]
17. Modulation in kinetics of lactone ring hydrolysis of camptothecins upon interaction with topoisomerase I cleavage sites on DNA.
Chourpa I; Riou JF; Millot JM; Pommier Y; Manfait M
Biochemistry; 1998 May; 37(20):7284-91. PubMed ID: 9585542
[TBL] [Abstract][Full Text] [Related]
18. SV40 DNA replication intermediates: analysis of drugs which target mammalian DNA replication.
Snapka RM; Permana PA
Bioessays; 1993 Feb; 15(2):121-7. PubMed ID: 8385943
[TBL] [Abstract][Full Text] [Related]
19. Early effects of topoisomerase I inhibition on RNA polymerase II along transcribed genes in human cells.
Khobta A; Ferri F; Lotito L; Montecucco A; Rossi R; Capranico G
J Mol Biol; 2006 Mar; 357(1):127-38. PubMed ID: 16427078
[TBL] [Abstract][Full Text] [Related]
20. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin.
Fujimori A; Harker WG; Kohlhagen G; Hoki Y; Pommier Y
Cancer Res; 1995 Mar; 55(6):1339-46. PubMed ID: 7882333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
